Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Global measles elimination.

Moss WJ, Griffin DE.

Nat Rev Microbiol. 2006 Dec;4(12):900-8. Epub 2006 Nov 6. Review.

PMID:
17088933
2.

The unfinished measles immunization agenda.

Strebel P, Cochi S, Grabowsky M, Bilous J, Hersh BS, Okwo-Bele JM, Hoekstra E, Wright P, Katz S.

J Infect Dis. 2003 May 15;187 Suppl 1:S1-7. Review.

PMID:
12721885
3.

Accelerated measles control in the Western Pacific region.

McFarland JW, Mansoor OD, Yang B.

J Infect Dis. 2003 May 15;187 Suppl 1:S246-51. Review.

PMID:
12721921
4.

Measles vaccine: do we need new vaccines or new programs?

Katz SL, Gellin BG.

Science. 1994 Sep 2;265(5177):1391-2. Review. No abstract available.

PMID:
8073281
5.

Measles elimination: progress and challenges.

Cutts FT, Henao-Restrepo A, Olivé JM.

Vaccine. 1999 Oct 29;17 Suppl 3:S47-52. Review.

PMID:
10559534
6.

Evaluating the impact of the HIV pandemic on measles control and elimination.

Helfand RF, Moss WJ, Harpaz R, Scott S, Cutts F.

Bull World Health Organ. 2005 May;83(5):329-37. Epub 2005 Jun 24. Review.

7.

[Current problems in the global elimination of measles].

Bektimirov TA.

Zh Mikrobiol Epidemiol Immunobiol. 1990 Sep;(9):104-8. Review. Russian. No abstract available.

PMID:
2256394
8.

Measles 50 Years After Use of Measles Vaccine.

Goodson JL, Seward JF.

Infect Dis Clin North Am. 2015 Dec;29(4):725-43. doi: 10.1016/j.idc.2015.08.001. Review.

PMID:
26610423
9.

Determining measles-containing vaccine demand and supply: an imperative to support measles mortality reduction efforts.

Costa A, Henao-Restrepo AM, Marie Hall S, Jarrett S, Hoekstra EJ.

J Infect Dis. 2003 May 15;187 Suppl 1:S22-8. Review.

PMID:
12721888
10.

Measles vaccination: new strategies and formulations.

de Vries RD, Stittelaar KJ, Osterhaus AD, de Swart RL.

Expert Rev Vaccines. 2008 Oct;7(8):1215-23. doi: 10.1586/14760584.7.8.1215. Review.

PMID:
18844595
11.

Field effectiveness of live attenuated measles-containing vaccines: a review of published literature.

Uzicanin A, Zimmerman L.

J Infect Dis. 2011 Jul;204 Suppl 1:S133-48. doi: 10.1093/infdis/jir102. Review.

PMID:
21666154
12.

Biological feasibility of measles eradication.

Moss WJ, Strebel P.

J Infect Dis. 2011 Jul;204 Suppl 1:S47-53. doi: 10.1093/infdis/jir065. Review.

13.

Measles virus 1998-2002: progress and controversy.

Rall GF.

Annu Rev Microbiol. 2003;57:343-67. Review.

PMID:
14527283
14.

Feasibility of global measles eradication after interruption of transmission in the Americas.

de Quadros CA, Andrus JK, Danovaro-Holliday MC, Castillo-Solórzano C.

Expert Rev Vaccines. 2008 Apr;7(3):355-62. doi: 10.1586/14760584.7.3.355. Review.

PMID:
18393605
15.
16.

Measles immunity and immunization in developing countries of Africa: a review.

Abdurrahman MB, Taqi AM.

Afr J Med Med Sci. 1981 Mar-Jun;10(1-2):57-62. Review.

PMID:
6287828
17.

The role of measles elimination in development of a national immunization program.

Orenstein WA.

Pediatr Infect Dis J. 2006 Dec;25(12):1093-101. Review.

PMID:
17133153
18.

Biological feasibility of measles eradication.

Bellini WJ, Rota PA.

Virus Res. 2011 Dec;162(1-2):72-9. doi: 10.1016/j.virusres.2011.09.023. Epub 2011 Sep 22. Review.

PMID:
21963661
19.

The theory of measles elimination: implications for the design of elimination strategies.

Gay NJ.

J Infect Dis. 2004 May 1;189 Suppl 1:S27-35. Review.

PMID:
15106086
20.

[Maternal and childhood immunization in developing countries: success, problems and new approaches].

Guerin N.

Med Trop (Mars). 2003;63(4-5):498-505. Review. French.

PMID:
14763306

Supplemental Content

Support Center